Jörg Timm

Jörg Timm

Auto-generated profile, based on publicly available information

Jörg Timm

Institute of Virology, Medical Faculty, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
BJBjörn-Erik Ole Jensen
Björn-Erik Ole Jensen
EKElena Knops
Elena Knops
LCLeon Cords
Leon Cords
NLNadine Lübke
Nadine Lübke
MSMaria Salgado
Maria Salgado
GKGuido Kobbe
Guido Kobbe
Despite scientific evidence originating from two patients published to date that CCR5Δ32/Δ32 hematopoietic stem cell transplantation (HSCT) can cure human immunodeficiency virus type 1 (HIV-1), the knowledge of immunological and virological correlates of cure is limited. Here we characterize a case of long-term HIV-1 remission of a 53-year-old male who was carefully monitored for more than 9 years after allogeneic CCR5Δ32/Δ32 HSCT performed for acute myeloid leukemia. Despite sporadic traces of HIV-1 DNA detected by droplet digital PCR and in situ hybridization assays in peripheral T cell subsets and tissue-derived samples, repeated ex vivo quantitative and in vivo outgrowth assays in humanized mice did not reveal replication-competent virus. Low levels of immune activation and waning HIV-1-specific humoral and cellular immune responses indicated a lack of ongoing antigen production. Four years after analytical treatment interruption, the absence of a viral rebound and the lack of immunological correlates of HIV-1 antigen persistence are strong evidence for HIV-1 cure after CCR5Δ32/Δ32 HSCT.

26 February 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
HKHelenie Kefalakes
Helenie Kefalakes
BBBettina Budeus
Bettina Budeus
AWAndreas Walker
Andreas Walker
CJChristoph Jochum
Christoph Jochum
GHGudrun Hilgard
Gudrun Hilgard
JTJoerg Timm
Joerg Timm
Activation of hepatitis B virus (HBV)–specific CD8 T cells by therapeutic vaccination may promote sustained control of viral replication by clearance of covalently closed circular DNA from infected hepatocytes. However, little is known about the exact targets of the CD8 T‐cell response and whether HBV reproducibly evades CD8 T‐cell immune pressure by mutation. The aim of this study was to address if HBV reproducibly selects substitutions in CD8 T‐cell epitopes that functionally act as immune escape mutations. The HBV core gene was amplified and sequenced from 148 patients with chronic HBV infection, and the human leukocyte antigen (HLA) class I genotype (A and B loci) was determined. Residues under selection pressure in the presence of particular HLA class I alleles were identified by a statistical approach utilizing the novel analysis package SeqFeatR. With this approach we identified nine residues in HBV core under selection pressure in the presence of 10 different HLA class I alleles. Additional immunological experiments confirmed that seven of the residues were located inside epitopes targeted by patients with chronic HBV infection carrying the relevant HLA class I allele. Consistent with viral escape, the selected substitutions reproducibly impaired recognition by HBV‐specific CD8 T cells. Conclusion: Viral sequence analysis allows identification of HLA class I–restricted epitopes under reproducible selection pressure in HBV core; the possibility of viral escape from CD8 T‐cell immune pressure needs attention in the context of therapeutic vaccination against HBV. (Hepatology 2015;62:47‐56)

10 October 2016 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
GLGahl Levy
Gahl Levy
NHNaomi Habib
Naomi Habib
MGMaria Angela Guzzardi
Maria Angela Guzzardi
DKDaniel Kitsberg
Daniel Kitsberg
DBDavid Bomze
David Bomze
YNYaakov Nahmias
Yaakov Nahmias

3 February 2021 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
LMLisa Müller
Lisa Müller
POPhilipp Niklas Ostermann
Philipp Niklas Ostermann
AWAndreas Walker
Andreas Walker
TWTobias Wienemann
Tobias Wienemann
AMAlexander Mertens
Alexander Mertens
TSTina Senff
Tina Senff
Evaluation and power of seroprevalence studies depend on the performed serological assays. The aim of this study was to assess four commercial serological tests from EUROIMMUN, DiaSorin, Abbott, and Roche as well as an in-house immunofluorescence and neutralization test for their capability to identify SARS-CoV-2 seropositive individuals in a high-prevalence setting. Therefore, 42 social and working contacts of a German super-spreader were tested. Consistent with a high-prevalence setting, 26 of 42 were SARS-CoV-2 seropositive by neutralization test (NT), and immunofluorescence test (IFT) confirmed 23 of these 26 positive test results (NT 61.9% and IFT 54.8% seroprevalence). Four commercial assays detected anti-SARS-CoV-2 antibodies in 33.3-40.5% individuals. Besides an overall discrepancy between the NT and the commercial assays regarding their sensitivity, this study revealed that commercial SARS-CoV-2 spike-based assays are better to predict the neutralization titer than nucleoprotein-based assays are.

1 October 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
SYShangqing Yang
Shangqing Yang
LWLu Wang
Lu Wang
WPWen Pan
Wen Pan
WBWibke Bayer
Wibke Bayer
CTChristine Thoens
Christine Thoens
JLJia Liu
Jia Liu

24 December 2014 in Medical Microbiology and Immunology
Verified
Journal Article
Open access
PDF file
JTJoerg Timm
Joerg Timm
CWChristopher M. Walker
Christopher M. Walker
Over the past two decades, much has been learned about how human viruses evade T cell immunity to establish persistent infection. The lessons are particularly relevant to two hepatotropic viruses, HBV and HCV, that are very significant global public health problems. Although HCV and HBV are very different, the natural history of persistent infections with these viruses in humans shares some common features including failure of T cell immunity. During recent years, large sequence studies of HCV have characterized intra-host evolution as well as sequence diversity between hosts in great detail. Combined with studies of CD8+ T cell phenotype and function, it is now apparent that the T cell response shapes viral evolution. In turn, HCV sequence diversity influences the quality of the CD8+ T cell response and thus infection outcome. Here, we review published studies of CD8+ T cell selection pressure and mutational escape of the virus. Potential consequences for therapeutic strategies to restore T cell immunity against persistent human viruses, most notably HBV, are discussed.